Antimicrobial resistance is a multifaceted crisis, imposing a serious threat to global health.
The traditional antibiotic pipeline has been exhausted, prompting research into alternate …

More than 3000 antimicrobial peptides (AMPs) have been discovered, seven of which have
been approved by the US Food and Drug Administration (FDA). Now commercialized, these …

Natural products are used since ancient times in folklore for the treatment of various
ailments. Plant‐derived products have been recognized for many years as a source of …

Staphylococcus aureus is capable of becoming resistant to all classes of antibiotics clinically
available and resistance can develop through de novo mutations in chromosomal genes or …

The global incidence of drug-resistant Gram-negative bacillary infections has been
increasing, and there is a dire need to develop novel strategies to overcome this problem …

Drug innovation is characterized by painstaking molecular-level syntheses and
modifications as the basic components of research and development. Similarly, natural …

The therapeutic areas of infectious diseases and oncology have benefited from abundant
scaffold diversity in natural products, able to interact with many specific targets within the cell …

Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant
bacteria, with vancomycin still a mainstream therapy against serious Gram-positive …

The biological activity of Mannich bases, a structurally heterogeneous class of chemical
compounds that are generated from various substrates through the introduction of an …

Despite efforts to develop new antibiotics, antibacterial resistance still develops too fast for
drug discovery to keep pace. Often, resistance against a new drug develops even before it …